Pancreatic Cancer Research

ResearcherLund UniversityActive in the last 2 years

Bodil Andersson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5591-0659; OpenAlex author ID A5074858718. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
87
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: none · 2024: 4 papers · 2025: none · 2026: 4 papers

Papers 21

  1. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.isci.2026.117352↗
  2. Digital quantification of stroma percentage enhances prognostic stratification in pancreatic cancer. Co-author DOI 10.1016/j.sopen.2026.01.002↗
  3. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  4. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  5. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  6. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis. Co-author DOI 10.1097/xcs.0000000000000971↗
  7. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  8. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  9. Preoperative Risk Score for Early Mortality After Up-Front Pancreatic Cancer Surgery: A Nationwide Cohort Study. Last author DOI 10.1007/s00268-022-06678-8↗
  10. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12094-021-02685-8↗
  11. Risk factors and outcomes for patients with pancreatic cancer undergoing surgical exploration without resection due to metastatic disease: A national cohort st… Last author DOI 10.1016/j.hbpd.2022.02.003↗
  12. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry. First author DOI 10.1080/00365521.2022.2078668↗
  13. Organoid technology for personalized pancreatic cancer therapy. Co-author DOI 10.1007/s13402-021-00585-1↗
  14. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm. Co-author DOI 10.1080/00365521.2018.1532020↗
  15. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. First author DOI 10.1080/00365521.2017.1290134↗
  16. Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-017-3834-z↗
  17. Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.12050↗
  18. Pancreatic cancer: yesterday, today and tomorrow. Co-author DOI 10.2217/fon-2016-0010↗
  19. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. Co-author DOI 10.1007/s00432-014-1817-x↗
  20. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Co-author DOI 10.1186/s13148-015-0139-4↗
  21. Artificial neural networks predict survival from pancreatic cancer after radical surgery. Last author DOI 10.1016/j.amjsurg.2012.05.032↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roland E. Andersson · 12 shared papers, 2013–2026 · strength 1.50
  2. Daniel Ansari · 12 shared papers, 2013–2026 · strength 1.50
  3. Bobby Tingstedt · 7 shared papers, 2013–2024 · strength 0.94
  4. Bergþór Björnsson · 5 shared papers, 2024–2026 · strength 0.82
  5. Marc G. Besselink · 4 shared papers, 2024–2026 · strength 0.67
  6. Paulina Bereza‐Carlson · 3 shared papers, 2022–2026 · strength 0.65
  7. Axel Bengtsson · 2 shared papers, 2021–2026 · strength 0.59
  8. Izaak Quintus Molenaar · 3 shared papers, 2024–2026 · strength 0.50
  9. Poya Ghorbani · 3 shared papers, 2024–2026 · strength 0.50
  10. Thomas F. Stoop · 3 shared papers, 2024–2026 · strength 0.50
  11. Roeland F. de Wilde · 3 shared papers, 2024–2026 · strength 0.50
  12. Christopher Lee Wolfgang · 3 shared papers, 2024–2026 · strength 0.50
  13. Marco Del Chiaro · 3 shared papers, 2024–2026 · strength 0.50
  14. Karin U. Johansen · 3 shared papers, 2024 · strength 0.48
  15. Tobias Keck · 3 shared papers, 2024 · strength 0.48
  16. Simone Augustinus · 3 shared papers, 2024 · strength 0.48
  17. Ulrich Friedrich Wellner · 3 shared papers, 2024 · strength 0.48
  18. Henry Anthony Pitt · 3 shared papers, 2024 · strength 0.48
  19. Bas Groot Koerkamp · 2 shared papers, 2024–2026 · strength 0.37
  20. Hjalmar C. van Santvoort · 2 shared papers, 2024–2026 · strength 0.37
  21. Asif Halimi · 2 shared papers, 2024–2026 · strength 0.35
  22. Ernesto Sparrelid · 2 shared papers, 2024–2026 · strength 0.35
  23. Jakob Kirkegård · 2 shared papers, 2024–2026 · strength 0.34
  24. Monika Posaric Bauden · 5 shared papers, 2015–2018 · strength 0.34
  25. Hanna Sternby · 1 shared paper, 2022 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.